Mason W. Freeman

Harvard University — United States

Medicine · Health Sciences

58h-index19.0kcitations145works14.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cholesterol and Lipid Metabolism(26), Diabetes Treatment and Management(20), Metabolism, Diabetes, and Cancer(19), Immune Response and Inflammation(18), Peroxisome Proliferator-Activated Receptors(16)

Publications145 total

Central Nervous System Biodistribution and Pharmacokinetics of Radiolabeled Tofersen in Rodents, Nonhuman Primates, and Humans
Journal of Nuclear Medicine·2025Open Access
Phase 2a Study of Baxdrostat in Primary Aldosteronism
New England Journal of Medicine·2025· 27 cited
Results from a Phase 1 Study Assessing the Pharmacokinetics of the Aldosterone Synthase Inhibitor Baxdrostat in Participants with Varying Degrees of Renal Function
Clinical Pharmacology in Drug Development·2024· 15 citedOpen Access
<scp>Meta‐analysis</scp> of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin
Diabetes Obesity and Metabolism·2023· 7 citedOpen Access
Author response for "&lt;scp&gt;Meta‐analysis&lt;/scp&gt; of risk of major adverse cardiovascular events in adults with type 2 diabetes treated with bexagliflozin"
2023
Bexagliflozin as an adjunct to metformin for the treatment of type 2 diabetes in adults: A 24‐week, randomized, double‐blind, placebo‐controlled trial
Diabetes Obesity and Metabolism·2023· 15 citedOpen Access
Results From a Randomized, Open-Label, Crossover Study Evaluating the Effect of the Aldosterone Synthase Inhibitor Baxdrostat on the Pharmacokinetics of Metformin in Healthy Human Subjects
American Journal of Cardiovascular Drugs·2023· 11 citedOpen Access
Automatización de pipelines de secuenciación de RNA en sistemas distribuidos
O2 - Repositori Institucional (Universitat Oberta de Catalunya)·2023
S-16-4: PHARMACOKINETICS, PHARMACODYNAMICS, AND SAFETY RESULTS FROM A PHASE 1 MULTIPLE ASCENDING DOSE STUDY OF THE SELECTIVE ALDOSTERONE SYNTHASE INHIBITOR CIN-107
Journal of Hypertension·2023
Results from a Randomized, Open-Label, Crossover Study Evaluating Pharmacokinetic Interaction Between the Aldosterone Synthase Inhibitor Baxdrostat and Metformin in Healthy Human Subjects
American Heart Journal·2022
Phase 2 Trial of Baxdrostat for Treatment-Resistant Hypertension
New England Journal of Medicine·2022· 315 citedOpen Access
Results From a Phase 1 Study Demonstrating the Safety and Pharmacokinetics of the Aldosterone Synthase Inhibitor CIN-107 in Subjects With Varying Degrees of Renal Function
Journal of the American Society of Nephrology·2022
Results from a phase 1, randomized, double-blind, multiple ascending dose study characterizing the pharmacokinetics and demonstrating the safety and selectivity of the aldosterone synthase inhibitor baxdrostat in healthy volunteers
Hypertension Research·2022· 62 citedOpen Access
Results from a phase 1 multiple ascending dose study demonstrating safety and selectivity of aldosterone synthase inhibitor CIN-107
European Heart Journal·2022· 1 citedOpen Access
A 96‐week, double‐blind, randomized controlled trial comparing bexagliflozin to glimepiride as an adjunct to metformin for the treatment of type 2 diabetes in adults
Diabetes Obesity and Metabolism·2022· 25 citedOpen Access
Author response for "A 96‐Week, Double‐Blind, Randomized, Controlled Trial Comparing Bexagliflozin to Glimepiride as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults"
2022
Author response for "A 96‐Week, Double‐Blind, Randomized, Controlled Trial Comparing Bexagliflozin to Glimepiride as an Adjunct to Metformin for the Treatment of Type 2 Diabetes in Adults"
2022
Correction for Jeyaseelan et al., “Distinct Roles of Pattern Recognition Receptors CD14 and Toll-Like Receptor 4 in Acute Lung Injury”
Infection and Immunity·2022· 1 citedOpen Access
An AAV-based, room-temperature-stable, single-dose COVID-19 vaccine provides durable immunogenicity and protection in non-human primates
Cell Host & Microbe·2021· 80 citedOpen Access
An overview of the process, progress, and outcomes of a National Center for Accelerated Innovation: The Boston Biomedical Innovation Center Experience
Journal of Clinical and Translational Science·2021· 1 citedOpen Access
page 1 of 8Next →

Frequent Co-authors

Kathryn J. Moore(14), Michael L. Fitzgerald(9), Douglas T. Golenbock(6), Monty Krieger(6), Lorna P. Andersson(5), Stephanie L. Koehn(5), Andrew D. Luster(4), John T. Potts(3), Lucia Rohrer(3), Vidya Kunjathoor(3), Marsha Penman(3), Mary McKee(3), Yuan‐Di C. Halvorsen(3), John Ashkenas(3), Susan A. Bell(3), Armando J. Mendez(3), Evan D. Rosen(2), Bruce M. Spiegelman(2), Abdul‐Badi Abou‐Samra(2), X F Kong(2)